We investigated 31 cases of pleomorphic carcinomas of the lung, with a double component of neoplastic epithelial cells and of spindle and/or giant cells. To correlate the morphologic diversity of these two cell components with their immunophenotype, we evaluated the expression of several gene products involved in cell differentiation (cytokeratins, epithelial membrane antigen, carcinoembryonic antigen, vimentin, S-100 protein, smooth muscle actin, desmin), cell cycle control and apoptosis (p53, p21 Waf1 , p27 Kip1 , FHIT), tumor growth (proliferative fraction, assessed by Ki-67 antigen, and microvascular density, assessed by CD34 immunostaining), and tumor cell motility (fascin). We found the epithelial component to be significantly more immunoreactive for cytokeratins, epithelial membrane antigen, carcinoembryonic antigen, cell cycle inhibitors p21
A mong non-small cell lung cancers (NSCLCs), tumors containing variable amounts of spindle and/or giant cells, or entirely made up of these cells, are uncommon but welldocumented entities.
Pathologists faced with these tumors have often experienced difficulties in rendering a definite diagnosis, especially because of the lack of uniformity in terminology and of standardized diagnostic criteria. Many designations have been proposed in the past to identify lung tumors containing true sarcomatous or sarcomatoid components, including biphasic and monophasic sarcomatoid carcinoma, pleomorphic carcinoma (PC), spindle cell carcinoma, giant cell carcinoma, pseudosarcoma, pulmonary blastoma, and carcinosarcoma. 1, 2, 5, 7, 8, 13, 15, 19, 20, 24, 27, 28, [35] [36] [37] 45, 51, 53 In the previous WHO classification, lung tumors showing a prevalence of spindle or giant cells were considered variant of squamous cell carcinomas and of large cell carcinomas, respectively. 52 The most recently updated WHO classification states that there exists "a group of poorly differentiated nonsmall cell lung cancer that contain a component of sarcoma or sarcoma-like elements." 49 Accordingly, PCs are defined as "a poorly differentiated NSCLC, namely squamous cell carcinoma, adenocarcinoma or large cell carcinoma, containing spindle cells and/or giant cells, or a carcinoma consisting only of spindle cells and giant cells. The pleomorphic component should comprise at least 10% of the neoplasm." Thus, the designation spindle cell carcinoma should be restricted to NSCLCs that are constituted exclusively of spindle cells; giant cell carcinoma to those composed of giant cells, and carcinosarcoma to those including heterologous elements such as malignant bone, cartilage, vessels or skeletal muscle. Spindle or giant cell tumors, however, are very uncommon in their pure form, 1, 51 and most of them fall in the category of PCs owing to the occurrence of a dual cell component. 49 Moreover, the rare occurrence of a sarcomatoid and a large cell neuroendocrine component in the same tumor 18 is now considered a variant of large cell neuroendocrine carcinoma. 49 The correct identification of PCs relies exclusively on pure histologic criteria without requiring any additional immunohistochemical or ultrastructural evidence. 49 Although the actual nature of the pleomorphic cells has been debated at length, an epithelial origin is currently accepted. Several studies have supported the view that epithelial tumor cells of PCs may acquire the expression of vimentin and of other mesenchymal markers, 1, 8, 27, 28, 37, 51, 53 and this phenotype may eventually result in spindling of the cells and reduced cell-to-cell adhesion. Few data, however, are available on the correlation between the morphologic diversities of the epithelial and sarcomatoid components within individual tumors and their corresponding immunophenotypes.
Another unresolved issue is whether PC has a different prognosis than conventional NSCLC. Some studies have reported PCs to be associated with more advanced disease stage at presentation and more aggressive clinical course, 5, 8, 19, 20, 28, 35, 37, 45, 51 but other investigations failed to demonstrate any significant poorer prognosis for PCs. 1, 27 This study was aimed at evaluating in a large series of PCs the different immunophenotypic features of the epithelial and the pleomorphic components within individual tumors, according to the expression of several gene products involved in cell differentiation (cytokeratins, epithelial membrane antigen [EMA], carcinoembryonic antigen [CEA], chromogranin A, synaptophysin, vimentin, S-100 protein, smooth muscle actin, desmin), cell cycle control and apoptosis (p53, p21
Waf1 , p27 Kip1 , FHIT), tumor growth (proliferative fraction assessed by KI-67 labeling and neoangiogenesis inferred by CD34 staining of endothelial cells), and tumor cell motility (fascin). Our results indicate that most of these markers are differentially expressed in the two tumor components and that they may be critical in inducing morphologic changes leading to the pleomorphic phenotype.
PATIENTS AND METHODS

Patients
Thirty-one patients with pulmonary PCs were identified in the files of the Departments of Pathology and Thoracic Surgery of the City Hospital in Verona (1987 Verona ( -1993 and the European Institute of Oncology in Milan (1998 Milan ( -2001 . For each case, all paraffin blocks were retrieved, and archival hematoxylin and eosin sections were reviewed. All patients had been studied preoperatively with clinical history, physical examination, respiratory tests, chest x-ray, total body CT scan, bone scintigraphy, and routine laboratory profile, and all underwent radical surgery. Only patients with a minimum 30-day postoperative survival were considered in the study. The clinical and demographic features of PCs are summarized in Table  1 . There were 28 males and 3 females, ranging in age from 39 to 79 years (mean ± SD, 62.4 ± 10.6 years; median 63 years). All but 5 patients had local or systemic symptoms at the time of the initial diagnosis, with Karnowsky performance status ranging from 70% to 100%. Complete follow-up information was available for all patients, with a mean duration of 36.5 ± 39.1 months (median 13 months; range 2-114 months). Recurrent disease at different sites was seen in 15 (48.3%) patients; 9 (29%) of them died of disease. Three patients died of unrelated disease (1 of acute gastric hemorrhage, 1 of adult respiratory distress syndrome, and 1 of acute heart failure). According to the revised international system for staging for lung cancer, 26 there were 16 patients with either p-stage IA (6 cases) or IB (10 cases), and 15 with either p-stage IIB (11 cases) or IIIA (4 cases). Two patients with disease stage IIB and IIIA underwent neoadjuvant chemotherapy, whereas no patients with disease stage I underwent any additional therapy.
The diagnosis of PC was rendered according to the current WHO guidelines. 49 The percentages and the types of the pleomorphic (spindle, giant cells, or mixed) and epithelial (adenocarcinoma, squamous cell carcinoma, or large cell carcinoma) components were assessed in every case by scanning the whole tumor. Tumor necrosis was evaluated semiquantitatively on a scale from absent to 2+ (1+, if <50%; 2+, if >50% of the whole tumor). The occurrence of vascular invasion within individual tumors was also recorded after CD34 immunostaining of the vascular channels, without discriminating the relative impact of arterial, venous and lymphatic invasion.
Immunohistochemistry
Formalin-fixed, paraffin-embedded surgical tissue samples were investigated in the study. Tumors were entirely immunostained if Յ3 cm in size, whereas at least two representative tissue blocks were evaluated in larger neoplasms. The immunohistochemical experiments were performed using the primary antibodies listed in Table 2 and a commercially available detection kit (EnVision Plus-HRP, Dako, Glostrup, Denmark), according to the manufacturer's suggestions and to previously refined methods. 32 Peroxidase activity was developed with 3-3Ј-diaminobenzidine-copper sulfate (Sigma Chemical Co, St Louis, MO) to obtain a brown-black end product. The specificity of all immunoreactions was doublechecked by substituting the primary antibodies with nonrelated isotypic mouse immunoglobulins at a comparable dilution, or with normal serum alone. Appropriate internal and external positive controls were also used in all immunostaining procedures to ensure specificity of reaction.
In each tumor, the pleomorphic and epithelial components were assessed separately, recording the percentage (labeling index) of neoplastic cells immunoreactive for cytokeratins, EMA, CEA, vimentin, S-100 protein, smooth muscle actin, desmin, fascin, p53, p21
Waf1 , p27 Kip1 , Ki-67 antigen, and FHIT. Only immunostaining products confined to the cytoplasm of tumor cells were taken into account for cytokeratins, EMA, CEA, chromogranin A, synaptophysin, vimentin, S-100 protein, smooth muscle actin, desmin, fascin, and FHIT. For p53, p21
Waf1
, and Ki-67 antigen, only nuclear accumulation was recorded in the corresponding labeling index, whereas p27
Kip1 immunoreaction could exhibit either cytoplasmic or nuclear decoration. To decrease the subjectivity of the scoring process, tumor cells were counted as positive if moderate to strong immunolabeling products were recognizable in either the cytoplasm or the nucleus as compared with appropriate internal or external controls. If reactivity was limited to few and minute particles of faint immunostaining, it was considered a trace reaction and not computed in the corresponding index. One observer (G.P.) evaluated all results of immunostaining blindly, without knowledge of the patients' identity or clinical outcome. For labeling indexes, the percentages of immunoreactive cells were obtained scanning at least 1,000 tumor cells in randomly selected fields: three different counts were obtained for each marker from either epithelial or sarcomatoid areas, and the highest score for each marker was chosen as the corresponding labeling index. For tumor angiogenesis, inferred by microvessel density (MVD) after CD34 immunostaining of endothelial cells, the mean number of vessels detected in three ×200 microscopic fields (each field corresponding to an area of 0.785 mm 2 ) in the hot spot areas was instead recorded.
Statistical Analysis
Associations of categorical variables were evaluated by Fisher exact test t test of 2 test. The comparison of continuous variables was performed using Wilcoxon's signed rank test for pairs. The intraobserver reproducibility was evaluated by analysis of variance. Overall survival was defined as the time between surgery and the last follow-up or cancer death. If a patient died without cancer recurrences, the patient's survival time was censored at the time of death. Only lung cancer related deaths or recurrences were considered as events. Disease-free survival was calculated from the date of surgery to the date of progression or the date of the last follow-up. Survival estimates were calculated with Kaplan-Meier's method and compared by the log-rank test. All analyses were carried out using the SAS statistical software (SAS Institute, Inc., Cary, NC). All P values were based on two-sided testing, and confidence intervals were set at a 95% level.
RESULTS
The pathologic findings are summarized in Table 3 .
Gross Findings
Grossly, the neoplasms ranged from 1.9 cm to 17 cm in size. Typically, the tumors showed areas of necrosis and hemorrhage, but a double component of sarcomatoid and carcinomatous areas could not be macroscopically suspected in all but one case (case no. 28) (Fig. 1 ).
Microscopic Findings
Representative features of PCs are depicted in Figure 2 . The epithelial components ranged from 10% to 85% of the whole tumor area and consisted of squamous cell carcinoma in 3 cases ( Fig. 2A) , adenocarcinoma in 14 cases (Fig. 2B) , and large cell carcinoma in 13 cases. One tumor (case no. 28) showed a triple epithelial component of bronchioloalveolar carcinoma, adenocarcinoma, and squamous cell carcinoma. The epithelial component was poorly differentiated in 24 tumors (13 large cell carcinomas, 9 adenocarcinomas, and 2 squamous cell carcinomas), whereas 6 cases showed an intermediate differentiation (5 adenocarcinomas and 1 squamous cell carcinoma). The tumor with triple epithelial component showed a well-differentiated bronchioloalveolar carcinoma and poorly differentiated adenocarcinoma and squamous cell carcinoma. The sarcomatoid component accounted for 15% to 90% of the tumor and was spindle in 5 cases ( Fig. 2A, C, D, E) , giant in 7 (Fig. 2B, F) or mixed in the remaining 19 cases. There was no preferential association between the different types of either epithelial and sarcomatoid components. The spindle cells component featured either relatively uniform spindle cells resembling fibrosarcoma or malignant nerve sheath tumor (Fig. 2C) or highly pleomorphic cells resembling malignant fibrous histiocytoma. The latter were arranged either haphazardly or in a fascicular or vaguely storiform configuration. The giant cell component consisted predominantly of bizarre giant cells with multilobated nuclei and abundant eosinophilic cytoplasm, which sometimes engulfed leukocytes (Fig. 2F) . The mixed type resulted from a variable proportion of highly atypical giant and spindle tumor cells, intimately admixed or segregated in distinct tumor areas. In some cases, especially those composed of spindle cells, the tumor matrix was at least partially myxoid (Fig. 2D) or contained a variable amount of leukocytes, plasma cells, and collagen fibers. Mitotic figures could be numerous, especially in spindle cell areas where prominent vascularization was also seen (Fig. 2E) . Tumor necrosis was encountered in all but 4 cases, ranging from focal (<50% of the whole tumor) in 11 cases to diffuse (>50%) in the remaining 16 tumors. Vascular invasion was recognizable in 18 (58%) cases, either within tumors or at the edge of the neoplastic masses, sometimes with evidence of disruption of the vascular elastic wall and luminal effacement by tumor cells. However, no systematic discrimination was made as for arterial, venous, or lymphatic invasion because of the relatively small number of examined tumors. There was no preferential distribution of tumor necrosis or vascular invasion in the two components, either epithelial or sarcomatoid.
Nine cases had lymph node metastases: in 5 cases, the metastases showed the same biphasic growth pattern as seen in the primary tumors, in 3 cases, only the epithelial component (ie, adenocarcinoma or squamous cell carcinoma) was identified; and in the last case, the metastasis was extensively necrotic and not further assessable.
No correlations were found between the percentage of pleomorphic cells within individual tumors and age, sex, performance status, vascular invasion, tumor necrosis, or tumor size. Only tumor stage was statistically related to the percentage of pleomorphic cells: stage I tumors were usually made up Յ50% of pleomorphic component, whereas the opposite occurred in stages II and III (Table 4) .
Immunohistochemical Findings
The results of the immunohistochemical study are detailed in Table 5 . Evaluation of intraobserver variation showed no statistically significant differences in immunostaining for all markers under evaluation in the whole series of tumors (F < 0.01, P > 0.90).
Cell Differentiation
The epithelial components, independent of the histologic type, tumor size, and stage were more consistently and more intensely immunoreactive for cytokeratins and EMA, whereas the opposite occurred for vimentin (Fig. 3A-D) . CEA immunostaining was observed in only 16 tumors but was significantly associated with the epithelial components. Occasional cells (<5%) were immunoreactive for smooth muscle actin, desmin, or S-100 protein, but they were confined to the sarcomatoid component, especially when spindle shaped. No tumor cells, either epithelial or sarcomatoid, displayed chromogranin A or synaptophysin immunoreactivity.
Cell Cycle Control and Apoptosis
Immunohistochemical expression of p21 Waf1 and p27
Kip1 proteins (the latter seen both in the nucleus and in the cytoplasm) was confined to the epithelial component. This was independent of tumor growth patterns, size, and stage of disease. FHIT gene product was more commonly upregulated in the epithelial components, although the differences were statistically significant only for tumors with stage >I. No differences were observed in the distribution of p53-immunoreactive cells between the two cell components (Fig.  3E, G, H) .
Tumor Cell Motility
Fascin immunoreactivity appeared as a fine, granular to diffuse cytoplasmic staining of both normal and neoplastic cells (Fig. 3F) . In the normal lung of either noncarcinoma or carcinoma patients' group, fascin immunoreactivity decorated invariably endothelial cells of bronchial and alveolar wall microvessels and dendritic cells of the mucosa-associated lymphoid tissue. Fascin immunoreactivity was most common in the pleomorphic areas, independent of tumor growth patterns, size, and stage of disease.
Tumor Growth
No statistically significant difference was observed in the distribution of Ki-67-immunoreactive cells between the two cell components, even after adjusting for tumor growth patterns, size, and stage of disease. MVD was more prominent in the pleomorphic component, independent of tumor growth patterns, size, and stage of disease.
Survival Data Analysis
Stage I tumors behaved more aggressively than ordinary NSCLCs, but differences in disease-free or overall survival were not statistically significant. About 50% of these patients died of disease or showed tumor recurrence after 5 years, a value strictly comparable with the clinical outcome of ordinary stage I NSCLCs (Fig. 4) . No survival analysis was performed in higher stage tumors because of the lack of adequately long follow-up time.
Moreover, we investigated whether the expression of different gene products involved in cell differentiation, cell cycle control, apoptosis regulation, tumor growth, and cell motility could have a prognostic relevance in PCs of the lung. In our study, however, only a Ki-67 labeling index >35% correlated negatively with both overall and disease-free survival (Table 6 ).
DISCUSSION
The occurrence of a sarcomatoid or pleomorphic component, with giant or spindle cells, is an uncommon but welldocumented feature in some NSCLCs, and it is usually considered to confer the neoplasms a more aggressive clinical course than ordinary lung cancer. 5, 8, 19, 20, 28, 35, 37, 45, 51 Although the nature of these pleomorphic cells has been debated at length, an epithelial derivation with divergent mesenchymal differentiation is now accepted. 28, 47 In the current study, we sought to correlate the morphologic diversity of the cell components of PCs with their immunophenotype for different molecules involved in cell differen-tiation, cell cycle control and apoptosis, tumor growth, and cell motility. From the results, we could derive a model of tumor morphogenesis, whereby the pleomorphic features of the neoplastic cells closely parallel the expression of the different gene products (Fig. 5) . Although we cannot exclude that some of these molecules studied are actually downstream covariants and that other genes are involved in the causative development of these tumors, we first indicate that epithelial and sarcomatoid cells in PCs of the lung are differentially regulated at the cellular level as far as the semiquantitative distribution of several molecules is concerned. This model is useful to summarize the statistically significant relationships between morphology and immunohistochemical results, without implying that the expression of the targets studied is able alone to induce epithelial-mesenchymal transition in these tumors.
The epithelial malignant component retains the expression of epithelial differentiation markers (ie, cytokeratins, CEA, and EMA), and consistently shows upregulation of the cell cycle inhibitors (ie, p21
Waf1 and p27 Kip1 ) and of FHIT, a molecule related to apoptosis. However, the pleomorphic component predominantly expresses cytoskeletal proteins of the mesenchymal type (vimentin, but occasionally also desmin and smooth muscle actin) and fascin, a cell motility-related protein, as well as shows increased levels of MVD, even though the pleomorphic cells may retain residual expression of cytokeratins and other epithelial markers. Altogether, these findings are consistent with a more severe dysregulation of several aspects of cellular life (cell cycle control, apoptosis, tumor growth, and cell motility) in the pleomorphic tumor cells, thus supporting the view that they may be an especially aggressive component of these tumors, albeit derived from epithelial cells. Interestingly, no tumor cells, either epithelial or sarcomatoid, displayed neuroendocrine differentiation as assessed by chromogranin A or synaptophysin immunoreactivity. This indicates that PCs can not be considered in the list of pulmonary tumors showing neuroendocrine differentiation. Although neuroendocrine properties may be unexpectedly detected in 10% to 20% of ordinary NSCLCs, especially adenocarcinomas and large cell carcinomas and less commonly squamous cell carcinomas, 5, 49 our results in PCs support the view that the engagement of neuroendocrine properties does not play an important role in the development and morphogenesis of these tumors.
It has been suggested that carcinoma cells may undergo a spectrum of progressive phenotypic changes that lead to the appearance of sarcomatoid features, via the activation of mesenchymally conditioned pathways resulting in the accumulation of vimentin and the loss of cytokeratin filaments. 6, 47 The cytoplasm reorganization confers higher plasticity to the tumor cells, which show reduced intercellular cohesion, due to the lack of keratin-based cell adhesion systems, progressive cell elongation with spindling, and reduced production of basement membranes with extracellular matrix invasion. 47 Many of these changes derive from cytoskeletal rearrangement, and the bundling of actin microfilaments at the cell periphery may play an important role in this change. Human fascin, a 55-kDa actin-bundling protein, is known to induce membrane protrusions at the leading edges of the cells and to increase cell motility of normal and transformed epithelial cells. 9, 23, 44, 46, 48, 54 It is therefore not surprising that fascin immunoreactivity is closely related to the pleomorphic phenotype, independent of tumor growth pattern, size, and stage. This suggests that fascin upregulation is an early event in the morphogenesis of PCs, and not a feature of more advanced tumors.
Down-regulation of p21 Waf1 and p27 Kip1 is also a consistent feature of the pleomorphic cell component of PCs, and an aberrant regulation of these cyclin-dependent kinase inhibitors has been commonly seen in the development of many types of human malignancies. 4, 14, 17, 21, 22, 29 These alterations are not accompanied by any corresponding abnormal accumulation of p53, in keeping with a previous study reporting no differential immunoreactivity for p53 in the epithelial and sarcomatoid components of pulmonary carcinosarcoma. The FHIT gene product, a tumor suppressor gene located at the 3p14.2 fragile site that is frequently and early deleted in lung cancerogenesis, 38, 40, 43 also shows a different prevalence in the two cell components of PCs, but only in higher stage carcinomas.
13
Finally, in the pleomorphic component an increased MVD may be documented, in keeping with previous data on the higher vascularization of sarcomatous than carcinomatous metastases to the lung. 50 This suggests that the pleomorphic component may acquire some phenotypic similarities to true sarcoma, even though it remains basically a carcinoma in its nature. A consequence of this finding, however, could be the possibility of using antiangiogenetic drugs in the management of these patients, although further studies are needed to confirm this assumption.
The selective distribution of most of the molecules under investigation strongly suggests that PC represents a distinct pathologic entity in the scenario of NSCLC. The differential regulation at the cellular level of several markers suggests the two cell components, either epithelial and sarcomatoid, are not simply the result of intratumoral heterogeneity of NSCLC. In fact, a similar differential distribution of these markers was not demonstrable within individual NSCLCs of conventional type when the latter were assessed in different areas of the same tumor (data not shown). As the sarcomatoid cells in our PCs retained variable phenotypic expressions of epithelial markers, we speculate that PCs are metaplastic carcinomas derived from trans-differentiation of malignant epithelial cells into sarcomalike cells. A metaplastic origin of biphasic PCs is also supported by a recent study on carcinosarcomas, a classic prototype of biphasic tumors of the lung. 13 In these neoplasms, a multistep progression of the sarcomatous component from common totipotent cells through an intermediate stage of carcinoma has been demonstrated, showing a greater amount of genetic damages in the mesenchymal than in the epithelial component. . FHIT was immunolocalized in epithelial tumor cells (E), whereas fascin reacted predominantly with the sarcomatoid elements (F). Similar results were achieved for both p27 Kip1 (with either nuclear or cytoplasmic labeling) (G) and p21
Waf1 (H) immunoreactivities: the epithelial components (on the left in G and at the bottom in H) were immunoreactive for both cell cycle inhibitors, whereas the sarcomatoid cells appeared to be consistently negative. A few p27 Kip1 -immunoreactive lymphocytes served as a helpful internal positive control (G).
Although PCs have been reported to run a more aggressive clinical course, 5, 8, 19, 20, 28, 35, 37, 45, 51 stage I tumors in our series did not show a significantly worse prognosis than ordinary NSCLCs; about 50% of the patients died of disease after 5 years, a value not different from that expected for patients with stage I ordinary NSCLC. 33 Our results are in keeping with those of Nakajima et al, who failed to demonstrate any significant clinical difference of sarcomatoid carcinomas as compared with conventional NSCLCs. 27 In our study, however, tumors with >50% pleomorphic cell component were more likely to belong to higher pathologic stages, suggesting that the percentage of sarcomatoid cells may be relevant to prognosis. 
FIGURE 4.
Overall (A) and disease-free (B) survival curves according to the different histology (adenocarcinoma, epidermoid carcinoma, and PC) in stage I NSCLC. Although there was a trend for stage I PC to behave more aggressively than ordinary NSCLC, differences were not statistically significant in both overall (A) and disease-free (B) survival curves. From a clinical viewpoint, the formal distinction of PCs from carcinosarcomas, according to the presence of true chondro-, osteo-, angio-, or rhabdomyosarcomatous components, may also be unwarranted because even carcinosarcomas do not show a significantly different prognosis. 19 Moreover, the threshold of 10% for the sarcomatoid component, as proposed by WHO for separating PCs from ordinary NSCLCs, is instrumental in excluding tumors with occasional sarcomatoid cells but is probably "per se" insufficient to identify lesions with distinct clinicopathologic characteristics that may result in different biologic behavior.
We also investigated whether the expression of different gene products involved in cell differentiation, cell cycle control, apoptosis regulation, tumor growth, and cell motility could have a prognostic significance in PCs of the lung. It is well known that downregulation of cell cycle inhibitors and of promoters of the apoptosis, and an increased tumor vascularization are associated with the progression of several tumor types. 10, 11, 16, 17, 22, 29, 34 Moreover, the subcellular localization of p27 kip1 , which has been reported to lead to protein inactivation and degradation, 42 and fascin overexpression could significantly contribute to the progression of PCs. We have recently found that fascin overexpression could be involved in the metastatic spread of stage I NSCLC via either direct vascular permeation or the development of newly formed microvessels (Pelosi et al., manuscript in preparation). However, in the current study, only a Ki-67 labeling index >35% was found to impact adversely on overall and disease-free survival, thus confirming the well-established prognostic role of Ki-67 immunostaining in several pulmonary and non-pulmonary neoplasms. 3, 12, 25, 30, 31, 33, 39, 42 In summary, this study supports the view that PCs, composed of a dual cell population of epithelial and sarcomatoid cells, represent a well-defined pathologic entity in the spectrum of NSCLC. We could construct a model of tumor morphogenesis whereby the sarcomatoid phenotype is closely correlated to specific changes in the expression of markers of cell differentiation, cell cycle control and apoptosis, tumor growth, and cell motility. Whereas stage I PCs do not prognostically differ from ordinary NSCLCs, the percentage of pleomorphic cells may have clinical relevance in more advanced-stage tumors.
